This past summer, the University of North Carolina School of Medicine presented early findings from the first completed randomized controlled trial of semaglutide in 48 people with AUD, which showed that those taking the medication reduced their drinking quantity and their heavy drinking more than a placebo group
[22] [23] Adverse effects [edit] Common side effects include low blood sugar, nausea, dizziness, abdominal pain, and pain at the site of injection
Subsequently, other drugs such as Novos Victoza (liraglutide, approved in 2010), AstraZenecas Bydureon (exenatide, 2012), GSKs Tanzeum (albiglutide, 2014), Lillys Trulicity (dulaglutide, 2014) and Novos Ozempic (semaglutide, 2017) and Rybelsus (oral semaglutide, 2019) were approved
So, Ozempic is expected to be effective regardless of whether its injected into the abdomen, thigh, or upper arm
Retatrutide is not referenced in any current NICE guidance, as it has not received regulatory approval